Protocol Systems (US) adds defibrillation to patient monitoring
This article was originally published in Clinica
Executive Summary
Protocol Systems (US) has acquired Omeara, a development-stage company based in Northern Ireland, for $426,000 and 145,000 shares of Protocol common stock. Omeara's primary technology - the universal defibrillator module (UDM) - and an external pacemaker will be incorporated into Protocol's Propaq Encore patient monitor and an integrated system is expected to be available in 1997.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.